Disease · MONDO_0019082
Trials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 26
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04206553 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Phase 2/3 | 106 | 2026-03-06 | Bullous Pemphigoid | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05267600 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Phase 2/3 | 98 | 2025-10-23 | Bullous Pemphigoid | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04612790 | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | Phase 3 | 67 | 2024-11-29 | Bullous Pemphigoid | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05681481 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Phase 3 | 64 | 2026-02-25 | Bullous Pemphigoid | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01688882 | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | Phase 2 | 20 | 2016-04-28 | Bullous Pemphigoid | LIGELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | Phase 2 | 11 | 2025-11-26 | Pemphigoid, Bullous | BERTILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00286325 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Phase 1/2 | 8 | 2012-10-22 | Bullous Pemphigoid | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04499235 | A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid | Phase 2 | 6 | 2023-09-14 | Pemphigoid, Bullous | LAZUCIRNON, MOMETASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT03099538 | Ixekizumab in the Treatment of Bullous Pemphigoid | Phase 2 | 4 | 2020-05-21 | Bullous Pemphigoid, Pemphigoid | IXEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02313870 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Phase 3 | 322 | Bullous Pemphigoid | CLOBETASOL PROPIONATE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | |
| NCT07210554 | Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid | Phase 3 | 200 | Bullous Pemphigoid (BP) | STAPOKIBART | Its record names the disease | ClinicalTrials.gov | |
| NCT02837965 | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | 149 | Bullous Pemphigoid | CLOBETASOL PROPIONATE, DOXYCYCLINE, METHOTREXATE, PREDNISONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05649579 | Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid | 146 | Bullous Pemphigoid | DUPILUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT00431119 | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid | Phase 2 | 70 | Bullous Pemphigoid | AZATHIOPRINE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00802243 | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid | Phase 2 | 54 | Bullous Pemphigoid | LEFLUNOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01705795 | Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Phase 2 | 32 | Pemphigoid, Bullous | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02872584 | Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids | 20 | Glucocorticoid | PREDNISONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT00525616 | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid | Phase 3 | 18 | Bullous Pemphigoid | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04117932 | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Phase 2 | 18 | Bullous Pemphigoid | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04465292 | The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid | Early phase 1 | 16 | Pemphigoid, Bullous | TILDRAKIZUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019082/trials